EUCTR2013-001439-34-ES
Active, not recruiting
Phase 1
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients - TERI-PRO
DrugsAubagio
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- Genzyme Corporation
- Enrollment
- 1001
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients with a relapsing form of MS (RMS)
- •\- Having signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 930
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 70
Exclusion Criteria
- •\- 18 years of age
- •\- Current or history of receiving teriflunomide
- •\- Previous treatment with leflunomide within 6 months prior to baseline
- •\- Patients with preexisting acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (ULN)
- •\- Known history of active tuberculosis (TB) or latent TB infection, either diagnosed by standard medical practice and guidelines (including skin or blood test, as appropriate) or according to local labeling
- •\- Known history of severe immunodeficiency, AIDS, bone marrow disease, acute or severe active infections
- •\- Women who are pregnant or breast\-feeding
- •\- Female patients with a positive pregnancy test at screening or women of child\-bearing potential who do not agree to use reliable contraception throughout the course of the study
- •\- Male patients: unwilling to use reliable contraception during the course of the study or according to local labeling
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-001439-34-DEGenzyme Corporation1,000
Active, not recruiting
Phase 1
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsEUCTR2013-001439-34-GBGenzyme Corporation1,000
Active, not recruiting
Phase 1
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisMedDRA version: 19.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-001439-34-FIGenzyme Corporation1,000
Active, not recruiting
Not Applicable
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisMedDRA version: 16.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-001439-34-ATGenzyme Corporation1,000
Active, not recruiting
Phase 1
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-001439-34-SEGenzyme Corporation1,000